Diabetes
News
FDA clears Abbott Freestyle Libre 3 glucose sensor
New features on the Freestyle Libre 3 system include real-time readings, improved accuracy, and smaller size.
From the Journals
SGLT2 inhibitors as first-line therapy in type 2 diabetes?
Real-world study finds heart failure hospitalization reduction, compared with metformin but not MI, stroke, or overall mortality and with greater...
From the Journals
Vitamin D doesn’t reduce type 2 diabetes risk ... or does it?
“Given how prevalent prediabetes and type 2 diabetes are, clinicians and patients should consider vitamin D supplementation as an adjunct to...
Guidelines
Experts endorse plant-based diet for type 2 diabetes remission
As a primary intervention, diet can achieve type 2 diabetes remission in many adults with normal or elevated BMI, and should be a plant-based,...
From the Journals
Metformin bombs in breast cancer in landmark trial
“Metformin is not effective against the most common types of breast cancer and any off-label use [of] this drug for the treatment of these common...
Feature
Newly approved tirzepatide’s retail price announced
The recently approved twincretin will carry a U.S. retail price similar to one of its main competitors, semaglutide, but patient discounts will be...
Commentary
Does COVID-19 raise the risk for diabetes?
Some data say yes and other data say no. Dr. Anne L. Peters sorts it out.
News
Many Americans missing an opportunity to prevent dementia
“Health care professionals should also screen patients for modifiable risk factors, counsel patients with risk factors, and refer them to...
Conference Coverage
Pancreatic involvement in COVID-19: What do we know?
“Our data identify the human pancreas as a target of SARS-CoV-2 infection and suggest that pancreatic beta cell involvement could contribute to...
From the Journals
Could new therapy for food ‘cues’ improve weight loss?
Patients highly sensitive to food ‘cues’ may benefit from behavioral therapy, but the intervention is labor intensive and tied to modest weight...
News
Tirzepatide (Mounjaro) approved for type 2 diabetes
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also...